Your browser doesn't support javascript.
loading
Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations.
Lindholm, Evita M; Krohn, Marit; Iadevaia, Sergio; Kristian, Alexandr; Mills, Gordon B; Mælandsmo, Gunhild M; Engebraaten, Olav.
Afiliação
  • Lindholm EM; Authors' Affiliations: Departments of Tumor Biology and Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital; Department of Oncology, Oslo University Hospital, Ullevaal and Institute of Clinical Medicine, University of Oslo, Oslo; Department of Pharmacy, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway; and Department of Systems Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Clin Cancer Res ; 20(2): 404-12, 2014 Jan 15.
Article em En | MEDLINE | ID: mdl-24192926

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Mama / Inibidores da Angiogênese / Proteoma / Proteômica / Antineoplásicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Mama / Inibidores da Angiogênese / Proteoma / Proteômica / Antineoplásicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article